Patents by Inventor James B. Kramer

James B. Kramer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic pyrazolyl thienopyridines
    Patent number: 9938289
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: April 10, 2018
    Assignee: FBM THERAPEUTICS, LLC
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • THERAPEUTIC PYRAZOLYL THIENOPYRIDINES
    Publication number: 20160200735
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 14, 2016
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • Therapeutic pyrazolyl thienopyridines
    Patent number: 9260450
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: February 16, 2016
    Assignee: THESAN PHARMACEUTICALS, INC.
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • Therapeutic pyrazolyl thienopyridines
    Patent number: 9090625
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 28, 2015
    Assignee: THESAN PHARMACEUTICALS, INC.
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • THERAPEUTIC PYRAZOLYL THIENOPYRIDINES
    Publication number: 20150175624
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Application
    Filed: March 3, 2015
    Publication date: June 25, 2015
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • THERAPEUTIC PYRAZOLYL THIENOPYRIDINES
    Publication number: 20140031385
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Application
    Filed: April 17, 2013
    Publication date: January 30, 2014
    Applicant: Medicis Phamaceutical Corporation
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • Therapeutic pyrazolyl thienopyridines
    Patent number: 8455512
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: June 4, 2013
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • Therapeutic Pyrazolyl Thienopyridines
    Publication number: 20110224251
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Application
    Filed: May 20, 2011
    Publication date: September 15, 2011
    Applicant: Graceway Pharmaceuticals, LLC
    Inventors: Stephen D. Barrett, Mark L. Boys, Huifen Chen, James B. Kramer
  • Therapeutic pyrazolyl thienopyridines
    Patent number: 7964612
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 21, 2011
    Assignee: Graceway Pharmaceuticals, LLC
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L Boys, Huifen Chen
  • Method of selectively inhibiting prostaglandin G/H synthase-2
    Patent number: 5571825
    Abstract: The present invention provides a method of selectively inhibiting prostaglandin G/H synthase-2 that comprises administering to a patient in need of such inhibition an inhibiting amount of a compound having the Formula I, II or III ##STR1## wherein the R groups and heterocycles are defined in the disclosure.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: November 5, 1996
    Assignee: Warner-Lambert Company
    Inventors: Diane H. Boschelli, David T. Connor, Richard D. Dyer, Sonya S. Khatana, James B. Kramer, William H. Roark
  • Benzothiophene, benzofuran and indole-thiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of HIV
    Patent number: 5565446
    Abstract: Benzothiophene, benzofuran and indolethiazepinones, oxazepinones and diazepinones as well as methods of preparation thereof are described as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases; these compounds also inhibit the activation of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 15, 1996
    Assignee: Warner-Lambert Company
    Inventors: Diane H. Boschelli, David T. Connor, James B. Kramer, Paul C. Unangst
  • Method for treating inflammatory disease in humans
    Patent number: 5489586
    Abstract: Benzothiophene, benzofuran and indole-thiazepinones, oxazepinones and diazepinones as well as methods of preparation thereof are described as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: February 6, 1996
    Assignee: Warner-Lambert Company
    Inventors: Diane H. Boschelli, David T. Connor, James B. Kramer, Paul C. Unangst
  • 3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas as 5-lipoxygenase inhibitors
    Patent number: 5442111
    Abstract: 3,5-Di-tertiary-butyl-4-hydroxyphenyloxy- or thioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas, and pharmaceutically acceptable base salts thereof, pharmaceutical compositions thereof, and methods of manufacture thereof are described. The compounds are said to be selective, potent 5-lipoxygenase inhibitors and useful in treating, for example, inflammatory and allergic conditions.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: August 15, 1995
    Assignee: Warner-Lambert Company
    Inventor: James B. Kramer
  • 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
    Patent number: 5434188
    Abstract: 1-Ether and 1-thioether-naphthalene-2-carboxamides are described, methods of manufacture therefor and their use as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases, and their utility in inhibiting the activation of human immunodeficiency virus (HIV), latent in infected humans.
    Type: Grant
    Filed: March 7, 1994
    Date of Patent: July 18, 1995
    Assignee: Warner-Lambert Company
    Inventors: Diane H. Boschelli, David T. Connor, Sony S. Khatana, James B. Kramer, Paul C. Unangst
  • 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
    Patent number: 5350748
    Abstract: 3-Thio or amino substituted benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted benzofuran-2-carboxamides are described as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases. Certain of these compounds are novel and methods of manufacture are also described.The same benzo[b]thiophene and benzofuran-2-carboxamides also inhibit the activation of human immunodeficiency virus (HIV), latent in infected mammals.
    Type: Grant
    Filed: August 18, 1993
    Date of Patent: September 27, 1994
    Assignee: Warner-Lambert Company
    Inventors: Diane H. Boschelli, David T. Connor, James B. Kramer, Paul C. Unangst
  • N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agents
    Patent number: 5112846
    Abstract: The present invention includes N-hydroxyamide, N-hydroxyurea, N-hydroxythioamide, and N-hydroxythiourea derivatives of fenamates, indomethacin, cicloprofen, oxepinac, and indoprofen as dual inhibitors or selective inhibitors of cyclooxygenase and 5-lipoxygenase.
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: May 12, 1992
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, Wiaczeslaw A. Cetenko, David T. Connor, Daniel L. Flynn, Catherine R. Kostlan, James B. Kramer, Jagadish C. Sircar
  • 3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues
    Patent number: 5102897
    Abstract: The novel 3,5-ditertiarybutyl-4-hydroxyphenylthio-1,3,4-thiadiazoles and oxadiazoles and 3,5-ditertiarybutyl-4-hydroxyphenylmethanone-1,3,4-thiadiazoles and oxadiazoles and related compounds of the present invention are antiinflammatory agents having activity as inhibitors of 5-lipoxygenase, cyclooxygenase or both.
    Type: Grant
    Filed: January 24, 1991
    Date of Patent: April 7, 1992
    Assignee: Warner-Lambert Company
    Inventors: Diane H. Boschelli, David T. Connor, Catherine R. Kostlan, James B. Kramer, Michael D. Mullican, Jagadish C. Sircar
  • N-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea derivatives of selected NSAIDS as antiinflammatory agents
    Patent number: 5075330
    Abstract: The present invention includes N-hydroxyamide, N-hydroxyurea, N-hydroxythioamide, and N-hydroxythiourea derivatives of fenamates, indomethacin, cicloprofen, oxepinac, and indoprofen as dual inhibitors or selective ihibitors of cyclooxygenase and 5-lipoxygenase.
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: December 24, 1991
    Assignee: Warner-Lambert Co.
    Inventors: Thomas R. Belliotti, Wiaczeslaw A. Cetenko, David T. Connor, Daniel L. Flynn, Catherine R. Kostlan, James B. Kramer, Jagadish C. Sircar
  • N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agents
    Patent number: 4981865
    Abstract: The present invention includes N-hydroxyamide, N-hydroxyurea, N-hydroxythioamide, and N-hydroxythiourea derivatives of fenamates, indomethacin, cicloprofen, oxepinac, and indoprofen as dual inhibitors or selective inhibitors of cyclooxygenase and 5-lipoxygenase.
    Type: Grant
    Filed: May 26, 1989
    Date of Patent: January 1, 1991
    Assignee: Warner-Lambert Co.
    Inventors: Thomas R. Belliotti, Wiaczeslaw A. Cetenko, David T. Connor, Daniel L. Flynn, Catherine R. Kostlan, James B. Kramer, Jagadish C. Sircar